Buradasınız

Anasayfa » Content

Potential role of RAGE protein expression in platelets and monocytes among the population with diabetes mellitus

Potential role of RAGE protein expression in platelets and monocytes among the population with diabetes mellitus

Journal Name:

  • Indian Journal of Basic & Applied Medical Research

Publication Year:

  • 2012

Key Words:

Author NameUniversity of Author
Abstract (2. Language): 
Background: Recent evidence suggests that RAGE may be a potential biomarker of diabetic vascular complications. The present study aimed to investigate the presence of RAGE in diabetes since RAGE up-regulation can be induced by AGEs. The two cell types chosen in this study were platelets and monocytes, which were isolated from human Type 2 diabetic subjects. Materials & Methods: Twenty Five newly diagnosed type 2 diabetic patients (13 males and 12 females) in the age group of 35-50 years were taken as case from our OP. As control, 25age matched healthy volunteers (13 males and 12 females) were recruited. The conducted investigations are RAGE levels in platelets and monocytes in human diabetic subjects Results:- The present study showed that human Type 2 diabetic subjects have significantly increased monocyte RAGE levels compared with human control subjects. RAGE levels in platelets were slightly increased but it is not significant. Conclusion:- It is clear that AGE-RAGE interaction plays a critical role in diabetes, a better understanding of RAGE expression in platelets and monocytes may provide a better means to understand diabetic vasculopathy. The ability of NSAIDs to down-regulate RAGE may be of importance in the management of diabetic complications.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-potential-role-rage-protein-expression-platelets-and-monocytes-among-population-diabetes-mellitus.pdf
  • 3
199-204
  • Turkish

REFERENCES

References: 

1. Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki
T, Ueda S & Horiuchi S. (1996) N (epsilon)-
(carboxymethyl)lysine protein adducts is a major
immunological epitope in proteins modified with advanced
glycation end products of the Maillard reaction. Biochem.
35:8075-8083
2. Sell DR & Monnier V. (1989) Structure elucidation of a
senescence cross-link from human extracellular matrix.
Implication of pentoses in the aging process. J Biol Chem.
264:21597-21602.
3. Facchiano F, Lentini A, Fogliano V, Mancarella S, Rossi C,
Facchiano A & Capogrossi MC. (2002) Sugar-induced
modification of fibroblast growth factor 2 reduces its angiogenic
activity in vivo. Am J Pathol. 161:531-541
4. Verzijl N, DeGroot J, Ben ZC, Brau-Benjamin O, Maroudas
A, Bank RA, Mizrahi J, Schalkwijk CG, Thorpe SR, Baynes
JW, Bijlsma JW, Lafeber FP & TeKoppele JM. (2002)
Crosslinking by advanced glycation end products increases the
stiffness of the collagen network in human articular cartilage: a
possible mechanism through which age is a risk factor for
osteoarthritis. Arthritis Rheum. 46:114-123.
5. Badenhorst D, Maseko M, Tsotetsi OJ, Naidoo A,
Brooksbank R, Norton GR & Woodiwiss AJ. (2003) Crosslinking
influences the impact of quantitative changes in
myocardial collagen on cardiac stiffness and remodeling in
hypertension in rats. Cardiovasc Res. 57:632-641.
6. Brett J, Schmidt AM, Zou YS, Yan SD, Weidman E, Pinsky
D, Neeper M, Przysiecki C, Shaw A, Migheli A & Stern D.
(1993) Survey of the distribution of a newly characterized
receptor for advanced glycation end products in tissues. Am J
Pathol. 143:1699-1712.
7.Renard C, Chappey O, Wautier MP, Nagashima M, Lundh E,
Morser J, Zhao L, Schmidt AM, Scherrmann JM & Wautier JL.
(1997) Recombinant advanced glycation end product receptor
pharmacokinetics in normal and diabetic rats. Mol Pharmacol.
52(1):54-62
8. Renard C, Chappey O, Wautier MP, Nagashima M, Morser J,
Scherrmann JM & Wautier JL. (1999) The human and rat
recombinant receptors for advanced glycation end products have
a high degree of homology but different pharmacokinetic
properties in rats. J Pharmacol Exp Ther. 290:1458-1466.
Indian Journal of Basic & Applied Medical Research; June 2012: Issue-3, Vol.-1, P. 199-204
203
www.ijbamr.com
9. Johnson, B.F., Nesto, R.W., Pfeifer, M.A., Slater, W.R.,
Vinik, A.I., Chyun, D.A., Law, G., Wackers, F.J., and
Young, L.H. (2004) Cardiac abnormalities in diabetic
patients with neuropathy: effects of aldose reductase
inhibitor administration. Diabetes Care, 27, 448–454.
10. Wautier JL, Zoukourian C, Chappey O, Wautier MP,
Guillausseau PJ, Cao R, Hori O, Stern D & Schmidt AM.
(1996) Receptor-mediated endothelial cell dysfunction in
diabetic vasculopathy. Soluble receptor for advanced
glycation end products blocks hyperpermeability in
diabetic rats. J Clin Invest. 97(1):238-43.
11. Maillard L. (1912) Action des acides amines sur les
sucres: formation des melanoidines par voie methodique. C
R Hebd Seances Acad Sci. 154:66-68.
12. Brownlee M, Cerami A & Vlassara H. (1988)
Advanced glycosylation end products in tissue and the
biochemical basis of diabetic complications. N Engl J Med.
318:315-1321.
13. Facchiano F, Lentini A, Fogliano V, Mancarella S,
Rossi C, Facchiano A & Capogrossi MC. (2002) Sugarinduced
modification of fibroblast growth factor 2 reduces
its angiogenic activity in vivo. Am J Pathol. 161:531-541.
14. Verzijl N, DeGroot J, Ben ZC, Brau-Benjamin O,
Maroudas A, Bank RA, Mizrahi J, Schalkwijk CG, Thorpe
SR, Baynes JW, Bijlsma JW, Lafeber FP & TeKoppele
JM. (2002) Crosslinking by advanced glycation end
products increases the stiffness of the collagen network in
human articular cartilage: a possible mechanism through
which age is a risk factor for osteoarthritis. Arthritis
Rheum. 46:114-123.
15. Badenhorst D, Maseko M, Tsotetsi OJ, Naidoo A,
Brooksbank R, Norton GR & Woodiwiss AJ. (2003) Crosslinking
influences the impact of quantitative changes in
myocardial collagen on cardiac stiffness and remodeling in
hypertension in rats. Cardiovasc Res. 57:632-641.
16. Park GY, Joo M, Pedchenko T, Blackwell TS &
Christman JW. (2004) Regulation of macrophage
cyclooxygenase-2 gene expression by modifications of
histone H3. Am J Physiol Lung Cell Mol Physiol.
286(5):L956-62
17. Kislinger T, Tanji N, Wendt T, Qu W, Lu Y, Ferran LJ
Jr, Taguchi A, Olson K, Bucciarelli L ,Goova M H,ofmann
MA, Cataldegirmen G, D'Agati V, Pischetsrieder M, Stern
DM & Schmidt AM (2001) RAGE mediates inflammation
and enhanced expression of tissue factor in the vasculature
of diabetic apolipoproteinE null mice. Arterioscler Thromb
Vasc Biol. 21:905-910.
18 Schmidt AM, Yan SD, Yan SF & Stern DM. (2001) The
multiligand receptor RAGE as a progression factor amplifying
immune and inflammatory responses. J Clin Invest. 108:949-955.
19. Buenting CE, Koschinsky T, Schwippert B, Ruetter R, Weiss
J, Roesen P & Tschoepe D. (2001) Food advanced glycation
endproducts induce activation of platelets by increasing
expression of receptors for AGE. 37th Annual meeting of the
European Association for the study of Diabetes, Glasgow, UK,
Sep 2001. 123.
20. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou
YS, Pinsky D & Stern D. (1994) Enhanced cellular oxidant stress
by the interaction of advanced glycation end products with their
receptors/binding proteins. J Biol Chem. 269:9889-9897.
21. Stenberg PE, McEver RP, Shuman MA, Jacques YV &
Bainton DF. (1985) A platelet α-granule membrane protein
(GMP-140) is expressed on the plasma membrane after
activation. J. Cell Biol. 101:880-886.
22. Nurden P, Poujol C, Winckler J, Combrie R, Pousseau N,
Conley PB, Levy-Toledano S, Habib A & Nurden AT. (2003)
Immunolocalization of P2Y1 and TPalpha receptors in platelets
showed a major pool associated with the membranes of alpha -
granules and the open canalicular system. Blood. 101(4):1400-8.
23. Buchs AE, Kornberg A, Zahavi M, Aharoni D, Zarfati C &
Rapoport MJ. (2004) Increased expression of tissue factor and
receptor for advanced glycation end products in peripheral blood
mononuclear cells of patients with type 2 diabetes mellitus with
vascular complications. Exp Diabesity Res. 5(2):163-9.
24. Brett J, Schmidt AM, Zou YS, Yan SD, Weidman E, Pinsky
D, Neeper M, Przysiecki C, Shaw A, Migheli A & Stern D.
(1993) Survey of the distribution of a newly characterized
receptor for advanced glycation end products in tissues. Am J
Pathol. 143:1699-1712.
25. Schmidt AM, Yan SD, Yan SF & Stern DM. (2001) The
multiligand receptor RAGE as a progression factor amplifying
immune and inflammatory responses. J Clin Invest. 108:949-955.
26. Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong LL,
Jenkins DG, Stein G, Schmidt AM & Yan SF. (2006) RAGE
modulates vascular inflammation and atherosclerosis in a murine
model of type 2 diabetes. Atherosclerosis. 185(1):70-7.
27. Cipollone F, Fazia ML, Iezzi A, Cuccurullo C, De Cesare D,
Ucchino S, Spigonardo F, Marchetti A, Buttitta F, Paloscia L,
Mascellanti M, Cuccurullo F & Mezzetti A. (2005) Association
between prostaglandin E receptor subtype EP4 overexpression
and unstable phenotype in atherosclerotic plaques in human.
Arterioscler Thromb Vasc Biol. 25(9):1925-31.
Indian Journal of Basic & Applied Medical Research; June 2012: Issue-3, Vol.-1, P. 199-204
204
www.ijbamr.com
28. Bucciarelli L, Wendt T, Qu W, Lu Y, Lalla E, Rong LL,
Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stern
DM & Schmidt AM. (2002) RAGE blockade stabilizes
established atherosclerosis in diabetic apolipoprotein-E-null
mice. Circulation.106:2827-2835.

Thank you for copying data from http://www.arastirmax.com